Pharmacogenomic Analysis of Response to Topical Tumor Necrosis Factor α Antagonist Licaminlimab (OCS-02) in Dry Eye Disease. (PubMed, Cornea) - Feb 28, 2024 - "The CC genotype of rs1800693, relatively common in patients with DED, was strongly associated with response to licaminlimab and decreased inflammatory cytokine gene expression in ocular surface cells during treatment. This study is one of the first to our knowledge to investigate pharmacogenomics in the treatment of DED."
Biomarker • Journal • Dry Eye Disease • Eye Cancer • Immunology • Ocular Inflammation • Ocular Melanoma • Oncology • Ophthalmology • Sjogren's Syndrome • CXCL8 • IL1B • TNFRSF1A
|
|
Anat Galor; Christophe Baudouin; Eric Donnenfeld; Georges Weissgerber; Victor L Perez; Yunsheng He
|